Last Updated : July 24, 2024
Details
Generic Name:
daratumumab
Project Status:
Not filed
Therapeutic Area:
Multiple myeloma, eligible for autologous stem cell transplant
Manufacturer:
Janssen Canada Inc.
Brand Name:
Darzalex
Project Line:
Reimbursement Review
Project Number:
NS0031-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
In combination with bortezomib, thalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024